Reinach B, de Sousa G, Dostert P, Ings R, Gugenheim J, Rahmani R
Pharmacia and Upjohn, Drug Metabolism Research, Nerviano, Italy.
Chem Biol Interact. 1999 Jun 1;121(1):37-48. doi: 10.1016/s0009-2797(99)00089-7.
The aim of this study was to evaluate rifabutin (RBT) and rifampicin (RIF) capabilities in inducing various xenobiotic metabolizing enzymes such as cytochromes P450 (CYPs) and UDP-glucuronosyl-transferases (UGTs) in cultured fresh and cryopreserved human hepatocytes. Enzyme induction was assessed through the use of several diagnostic markers, i.e. testosterone, midazolam (MDZ), diazepam (DZP) and 7-ethoxyresorufin for CYP-dependent enzyme reactions; and AZT for UGT-dependent enzyme reactions. RBT concentrations (0.118, 0.708 microM) were selected according to previously published pharmacokinetic data in patients. The known CYP3A4 inducer in humans, RIF, was used as a positive control. At the concentrations used, no sign of cytotoxicity was evidenced. Both compounds were able to dose-dependently induce the overall metabolism of testosterone (approximately 2-fold for RBT, 4-fold for RIF) and the formation of the 6beta-hydroxylated-derivative (up to approximately 4-fold over control for RBT and approximately 10-fold for RIF), which is CYP3A4 dependent. The other hydroxylated metabolites (16alpha-OH and 2alpha-OH) were also enhanced. The metabolism of MDZ, which is specifically metabolized by CYP3A4 in humans, was also investigated following drug's exposure to hepatocytes. DZP one, which is governed by various CYPs, including CYP3A, was also investigated. RBT was shown to increase the biotransformation of both benzodiazepines (approximately 1.9-fold over control). Moreover, the effects of both drugs on ethoxyresorufin O-deethylase activity (EROD), which is representative of CYPIA1/2 isoforms, were tested. Results showed only a moderate induction of this marker (approximately 2-fold over control) when compared to the high effect observed after hepatocyte exposure to 3-methylcholantene (approximately 14-fold over control). Finally, the action of RBT and RIF on UGTs expression was investigated by using AZT as diagnostic substrate: glucuronides formation was not significantly affected by the two rifamycin derivatives. On the whole, exposure of fresh or cryopreserved human hepatocytes to RBT dose-dependently affected the levels of drug metabolizing enzymes in a dose-dependent manner. However, as already demonstrated by in vivo pharmacokinetic studies, its inducing properties towards CYPs, CYP3A in particular, are less pronounced than RIF.
本研究的目的是评估利福布汀(RBT)和利福平(RIF)在培养的新鲜和冷冻保存的人肝细胞中诱导各种外源性物质代谢酶的能力,这些酶包括细胞色素P450(CYPs)和尿苷二磷酸葡萄糖醛酸基转移酶(UGTs)。通过使用几种诊断标志物来评估酶诱导,即用于CYP依赖性酶反应的睾酮、咪达唑仑(MDZ)、地西泮(DZP)和7-乙氧基试卤灵;以及用于UGT依赖性酶反应的齐多夫定(AZT)。根据先前发表的患者药代动力学数据选择RBT浓度(0.118、0.708微摩尔)。人类已知的CYP3A4诱导剂RIF用作阳性对照。在所使用的浓度下,未发现细胞毒性迹象。两种化合物均能够剂量依赖性地诱导睾酮的整体代谢(RBT约为2倍,RIF约为4倍)以及6β-羟基化衍生物的形成(RBT比对照高出约4倍,RIF约为10倍),这是CYP3A4依赖性的。其他羟基化代谢物(16α-OH和2α-OH)也有所增加。在药物暴露于肝细胞后,还研究了在人类中由CYP3A4特异性代谢的MDZ的代谢。还研究了由包括CYP3A在内的各种CYPs调控的DZP的代谢。结果表明,RBT可增加两种苯二氮䓬类药物的生物转化(比对照高出约1.9倍)。此外,测试了两种药物对乙氧基试卤灵O-脱乙基酶活性(EROD)的影响,EROD代表CYPIA1/2亚型。与肝细胞暴露于3-甲基胆蒽后观察到的高效应(比对照高出约14倍)相比,结果仅显示该标志物有中度诱导(比对照高出约2倍)。最后,通过使用AZT作为诊断底物研究了RBT和RIF对UGTs表达的作用:两种利福霉素衍生物对葡萄糖醛酸苷形成没有显著影响。总体而言,新鲜或冷冻保存的人肝细胞暴露于RBT会剂量依赖性地影响药物代谢酶的水平。然而,正如体内药代动力学研究所证明的那样,其对CYPs,特别是CYP3A的诱导特性不如RIF明显。